Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab + Apatinib + Irinotecan in Advanced AFP-producing Gastric Cancer
NCT07289997Phase 2Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by The Fourth Hospital of Hebei Medical University. Started Sep 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07289997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07289997.